摘要
目的探讨分析曲美他嗪对冠状动脉介入治疗后的临床疗效。方法回顾性分析心血管内科2009年2月～2011年10月收治的经皮冠状动脉介入治疗(PCI)的患者120例,将其随机分为实验组和对照组两组,每组各60例,实验组在术后服用曲美他嗪20mg tid,服用3周,同时接受常规手术用药。而对照组仅应用常规药物。术后24h测定患者的心肌肌钙蛋白(IcTnI)等含量,术后4周复查心脏彩超左室射血分数。结果术后24h实验组cTnI升高幅度明显低于对照组,差异均具有统计学意义(P<0.05)。而两组术后CK-MB变化幅度没有明显差异(P>0.05)。实验组治疗后LVEF指数升高显著高于术前,差异具有统计学意义(P<0.05)。表明实验组心功能在治疗显著好转。结论曲美他嗪在PCI治疗后具有较好心肌保护作用,值得在临床上推广。
Objective To investigate the clinical efficacy of trimetazidine in PCI.Methods A analysis of our hospital in February 2009 to 2011 October 120 PCI patients were randomly divided into experimental group and control group,n = 60 cases,24h after determination of patients with cTnI and other content,and after four weeks to review LVEF.Results The postoperative CK-MB and cTnI levels were significantly higher than before PCI.And 24h after surgery,cTnI increased the magnitude of the experimental group was significantly lower than the control group,the differences were statistically significant（P0.05）.Experimental group after treatment,LVEF index increased significantly higher than before surgery,a statistically significant difference（P0.05）.The experimental group significantly improved cardiac function in the treatment.Conclusion Trimetazidine hydrochloride in PCI after treatment with better myocardial protection,it is worth in clinical practice.
出处
《当代医学》
2012年第12期153-154,共2页
Contemporary Medicine
